Summary:
HAVE YOU BEEN RECENTLY DIAGNOSED WITH PARKINSON’S DISEASE?
If so, the SPARK clinical study may be of interest to you.
The SPARK study is for people who have been recently diagnosed with Parkinson’s disease and are looking to take a proactive step in their care. We are evaluating an investigational drug to see if it may offer patients a way to potentially treat Parkinson’s disease in its earliest stages.
ALPHA-SYNUCLEIN AND THE INVESTIGATIONAL DRUG
One of the hallmarks of Parkinson’s disease is the presence of clumps of proteins that occur within the nerve cells in the brain, called Lewy bodies. Researchers believe that the molecule alpha-synuclein may potentially play a major role in the formation and development of these harmful Lewy bodies and, by extension, Parkinson’s disease progression.
The investigational drug is designed to attach to alpha-synuclein molecules and is being studied to see if it may prevent them from causing damage.
SPARK researchers believe this type of approach could potentially help slow or delay disease progression in people who are in the earliest stages of Parkinson’s disease.
WHO CAN JOIN?
For the SPARK study, you may be eligible to participate if you:
- Are 40 to 80 years old
- Have been diagnosed within the last 3 years
- Have not received levodopa or other Parkinson’s disease medications in the last 12 weeks
WHY PARTICIPATE?
All eligible study participants will receive at no cost:
- Study drug (investigational drug or placebo)
- Study-related care and consultation with a study doctor
- Study office visits and health assessments
- Travel Assistance
- Reimbursement
AM I ELIGIBLE?